Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management.

Scientific Reports
Tamar BergerOren Pasvolsky

Abstract

There is paucity of data regarding the diagnostic yield and safety of skin biopsies in patients with acute myeloid leukemia (AML), though skin eruptions are common in these patients. We evaluated 216 patients treated in our hemato-oncology unit at a tertiary medical center between 2007 and 2018 and identified 35 patients who underwent 37 skin biopsies. The majority of biopsies were performed during induction treatment for AML (n = 26, 70%), whereas the remainder of biopsies were done prior to induction initiation (n = 8, 22%) or during consolidation chemotherapy (n = 3, 8%). Pathology findings were inconclusive in 13 cases (35%), while diagnostic biopsies were positive for drug eruptions (24%), leukemia cutis (16%), infections (11%), reactive processes (8%) and Sweet syndrome (5.5%). In almost half of cases (16/37) tissue cultures were performed. Of those, only a quarter (4/16) were positive. Histopathology and tissue culture results altered immediate patient care in 3 cases (8%), yet information obtained from biopsies had potential to affect long term patient care in 8 additional cases (21.6%). Although most skin biopsies were performed while patients had severe thrombocytopenia and neutropenia, only one patient had a complica...Continue Reading

References

Nov 1, 2000·JAMA : the Journal of the American Medical Association·S C HowardC H Pui
Feb 21, 2006·Clinical and Experimental Dermatology·K M T WatsonD Creamer
Jan 21, 2011·The New England Journal of Medicine·Lindsay Rosenbeck, Patrick J Kiel
Jul 29, 2011·Blood·Richard L BakstJoachim Yahalom
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·George L AnesiAmir T Fathi
Sep 13, 2013·The New England Journal of Medicine·Jacob LevittTalley Whang
Nov 11, 2014·Annals of Internal Medicine·Richard M KaufmanAaron A R Tobian
Nov 25, 2014·Haematologica·Richard F Schlenk
Sep 17, 2015·The New England Journal of Medicine·Hartmut DöhnerClara D Bloomfield
Apr 17, 2017·Journal of the American Academy of Dermatology·Fan Di XiaArash Mostaghimi

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.